News and Announcements
Specialised Therapeutics Australia Supporting OncoSil Study
- Published April 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, will collaborate with independent biopharmaceutical company Specialised Therapeutics Australia (STA) to support the company’s global clinical study program examining OncoSil Medical’s proprietary technology in combination with different chemotherapy regimens.
KEY TAKEAWAYS:
- Independent pharmaceutical company Specialised Therapeutics Australia (STA) to support Oncosil Medical global Pancreatic Cancer study.
- STA to supply subsidised ABRAXANE®(nanoparticle albumin-bound paclitaxel) to Australian sites for clinical study.
- ABRAXANE® is marketed in Australia by STA under license from Celgene Corporation.
- Majority of patients recruited at five key Australian trial sites expected to be provided gemcitabine plus ABRAXANE® chemotherapy combination.
Under the terms of the arrangement, STA has authorised a significantly-subsidised supply of ABRAXANE to be used by all Australian sites participating in the global study. STA markets ABRAXANE® in Australia & New Zealand exclusively under license from the Celgene Corporation.
Australian study participants will all receive OncoSil™ plus FOLFIRINOX, or Oncosil plus a gemcitabine/ABRAXANE combination chemotherapy treatment. It is expected that most Australian patients enrolled will receive the gemcitabine/ABRAXANE chemotherapy combination.
STA Chief Executive Officer Mr Carlo Montagner said he was pleased to collaborate with Oncosil on the global study and looked forward to potentially changing treatment paradigms for pancreatic cancer.
Commenting on support of the trial, OncoSil Chief Executive Officer, Daniel Kenny said:
“We are extremely pleased to receive the generous support of Specialised Therapeutics Australia for the Australian arm of our global pancreatic study, and are greatly encouraged by the interest our study continues to generate globally.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
